Evidence map›Paper›PMID 28125743›Full record

ArticlePloS one2017

Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.

Sian Huish, Craig Thelwell, Colin Longstaff

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. M1 protein from group ABlood vessels, thrombosis & hemostasis · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Structural Biology and Protein Engineering of Thrombolytics.Computational and structural biotechnology journal · 2019
    Review
  7. Design of a DNA-Programmed Plasminogen Activator.Journal of the American Chemical Society · 2018
    Article
  8. Measuring fibrinolysis: from research to routine diagnostic assays.Journal of thrombosis and haemostasis : JTH · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sian HuishComponent development laboratory, NHS Blood and Transplant, Cambridge Donor Centre, Cambridge, United Kingdom.
Craig ThelwellBiotherapeutics Section, National Institute for Biological Standard and Control, South Mimms, Herts, United Kingdom.
Colin LongstaffBiotherapeutics Section, National Institute for Biological Standard and Control, South Mimms, Herts, United Kingdom.ORCID http://orcid.org/0000-0001-7608-208X
National Institute for Biological Standards and Control · GBNHS Blood and Transplant · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptokinase is a virulence factor of streptococci and acts as a plasminogen activator to generate the serine protease plasmin which promotes bacterial metastasis. Streptokinase isolated from group C streptococci has been used therapeutically as a thrombolytic agent for many years and its mechanism of action has been extensively studied. However, group A streptococci are associated with invasive and potentially fatal infections, but less detail is available on the mechanism of action of streptokinase from these bacteria. We have expressed recombinant streptokinase from a group C strain to investigate the therapeutic molecule (here termed rSK-H46A) and a molecule isolated from a cluster 2a strain from group A (rSK-M1GAS) which is known to produce the fibrinogen binding, M1 protein, and is associated with life-threatening disease. Detailed enzyme kinetic models have been prepared which show how fibrinogen-streptokinase-plasminogen complexes regulate plasmin generation, and also the effect of fibrin interactions. As is the case with rSK-H46A our data with rSK-M1GAS support a "trigger and bullet" mechanism requiring the initial formation of SK•plasminogen complexes which are replaced by more active SK•plasmin as plasmin becomes available. This model includes the important fibrinogen interactions that stimulate plasmin generation. In a fibrin matrix rSK-M1GAS has a 24 fold higher specific activity than the fibrin-specific thrombolytic agent, tissue plasminogen activator, and 15 fold higher specific activity than rSK-H46A. However, in vivo fibrin specificity would be undermined by fibrinogen stimulation. Given the observed importance of M1 surface receptors or released M1 protein to virulence of cluster 2a strain streptococci, studies on streptokinase activity regulation by fibrin and fibrinogen may provide additional routes to addressing bacterial invasion and infectious diseases.

Indexed as

Models, TheoreticalFibrinFibrinogenPlasminogenStreptococcus pyogenesStreptokinaseFibrinFibrinogenPlasminogenStreptokinase

Identifiers

PMID28125743
PMCPMC5268773
OpenAlexW2580873251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.